Cyclosporine Patent Expiration
Cyclosporine was first introduced by Novartis Pharmaceuticals Corp
Cyclosporine Patents
Given below is the list of patents protecting Cyclosporine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vevye | US12059449 | Ophthalmic composition for treatment of dry eye disease | Apr 01, 2042 | Harrow Eye |
| Vevye | US11413323 | Ophthalmic composition for treatment of dry eye disease | Oct 11, 2039 | Harrow Eye |
| Vevye | US11154513 | Semifluorinated compounds | Nov 20, 2038 | Harrow Eye |
| Vevye | US10813976 | Ophthalmic compositions comprising ciclosporin | Sep 22, 2037 | Harrow Eye |
| Cequa | US10918694 | Topical cyclosporine-containing formulations and uses thereof | Feb 28, 2037 | Sun Pharm |
| Cequa | US11951153 | Topical cyclosporine-containing formulations and uses thereof | Feb 28, 2037 | Sun Pharm |
| Vevye | US12496326 | Ophthalmic Composition For Treatment Of Dry Eye Disease | Sep 29, 2036 | Harrow Eye |
| Restasis Multidose | US9669974 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids | May 11, 2034 | Abbvie |
| Restasis Multidose | US9676525 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids | Feb 07, 2034 | Abbvie |
| Cequa | US10441630 | Topical formulations and uses thereof | Aug 23, 2033 | Sun Pharm |
| Cequa | US8980839 | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof | Aug 23, 2033 | Sun Pharm |
| Cequa | US9937225 | Topical formulations and uses thereof | Aug 23, 2033 | Sun Pharm |
| Restasis Multidose | US8561859 | Dispensing device | Apr 16, 2032 | Abbvie |
| Restasis Multidose | US8292129 | Dispensing device | Feb 25, 2031 | Abbvie |
| Vevye | US8614178 | Pharmaceutical composition for treatment of dry eye syndrome | Dec 13, 2030 | Harrow Eye |
| Verkazia | US9132071 | Compositions containing quaternary ammonium compounds | Jun 02, 2029 | Harrow Eye |
| Verkazia | US8298568 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential | Nov 03, 2027 | Harrow Eye |
| Verkazia | US11612658 | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
Jan 27, 2026
(Expired) | Harrow Eye |
| Verkazia | US7973081 | Emulsion compositions containing quaternary ammonium compounds |
Jan 27, 2026
(Expired) | Harrow Eye |
| Verkazia | US8524779 | Emulsion compositions containing quaternary ammonium compounds |
Jan 27, 2026
(Expired) | Harrow Eye |
| Verkazia | US9220694 | Emulsion compositions containing cetalkonium chloride |
Jan 27, 2026
(Expired) | Harrow Eye |
| Verkazia | US9956289 | Emulsion compositions containing quaternary ammonium compounds |
Jan 27, 2026
(Expired) | Harrow Eye |
| Restasis | US8629111 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis | US8633162 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis | US8642556 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis | US8648048 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis | US8685930 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis | US9248191 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US8629111 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US8633162 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US8642556 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US8648048 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US8685930 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Restasis Multidose | US9248191 | Methods of providing therapeutic effects using cyclosporin components |
Aug 27, 2024
(Expired) | Abbvie |
| Neoral | US5985321 | Soft gelatin capsule manufacture |
Sep 26, 2014
(Expired) | Novartis |
| Restasis | US5474979 | Nonirritating emulsions for sensitive tissue |
May 17, 2014
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cyclosporine's patents.
Latest Legal Activities on Cyclosporine's Patents
Given below is the list recent legal activities going on the following patents of Cyclosporine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Feb, 2026 | US11413323 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Oct, 2025 | US9956289 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jun, 2025 | US8614178 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Apr, 2025 | US11154513 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Apr, 2025 | US8561859 |
| Patent eCofC Notification | 18 Feb, 2025 | US11154513 |
| Recordation of Patent eCertificate of Correction | 18 Feb, 2025 | US11154513 |
| Mail Patent eCofC Notification | 18 Feb, 2025 | US11154513 |
| Email Notification | 18 Feb, 2025 | US11154513 |
| Post Issue Communication - Certificate of Correction | 31 Jan, 2025 | US11154513 |
About Veterinary Cyclosporine
Cyclosporine is used in drugs marketed by 5 different companies: Virbac Ah Inc, Ceva Sante Animale, Elanco Us Inc, Intervet Inc, Dechra Veterinary Products Llc.
Other drugs containing Cyclosporine are: Modulis for dogs , Atopica , Optimmune , Cyclavance
Cyclosporine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cyclosporine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Cyclosporine has 1 clinical trial that has been verified in 2024.
